Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

By Ludwig Burger FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Genentech, a member of the Roche Group, has announced positive results from the first of two phase 3 trials investigating ...

Roche's late-stage trial of fenebrutinib, a multiple sclerosis drug candidate, met its primary goal. The trial demonstrated a significant reduction in annualized relapse rates compared to ...

If Roche's fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

The Swiss drugmaker reported that its Phase III trial known as FENhance 2 met its main goal in patients with relapsing multiple sclerosis. Fenebrutinib, taken twice daily, significantly reduced the ...